MedPath

Epidural Dexamethasone Versus Betamethasone for Treatment of Lumbosacral Radiculalgia

Phase 4
Conditions
Chronic Pain
Interventions
Registration Number
NCT02833116
Lead Sponsor
Basque Health Service
Brief Summary

This study evaluate the administration of epidural betamethasone versus dexamethasone for pain reduction, consumption of analgesic and quality of life. Half of the patient will receive dexametasone and the other half betametasone.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
320
Inclusion Criteria
  • Unilateral leg pain secondary to lateral stenosis, disc protrusion or herniated disc.
  • Age between 18 and 80 years.
  • Moderate to severe pain (NVS>4).
  • Right proficient oral and written language.
Exclusion Criteria
  • Patients with high intracranial pressure.
  • Patients with Multiple Sclerosis.
  • Patients with Guillain-Barré syndrome radiculopathy of vascular origin.
  • Patients with previous lumbar surgery.
  • Patients pregnant or lactating.
  • Patients with allergy or intolerance to any of the drugs used.
  • Patients with severe cognitive impairment.
  • Patients with intrathecal injectio radiculalgia.
  • Patients with poorly controlled major psychiatric pathology.
  • Patients with type I diabetes or poorly controlled type II diabetes (Hb1Ac>8.5).
  • Patients with glaucoma.
  • Patients with caudal equine syndrome.
  • Patients with pre-treatment with steroid injections/or local anesthetics.
  • Patients with central canal stenosis.
  • patients with chronic treatment with oral corticosteroids without stabilized pattern.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group BetamethasoneBetamethasoneOne ampule containing 12 mg of betamethasone in a syringe of 10 ml
Group DexamethasoneDexamethasoneOne ampule containing 4 mg of dexamethasone in a syringe os 10 ml
Primary Outcome Measures
NameTimeMethod
Pain.3 months.

Pain according to numerical visual pain scale.

Secondary Outcome Measures
NameTimeMethod
Quality of life.7 days, 1, 3 and 6 months.

Quality of life according to SF-36.

Pain.7 days, 1, 3 and 6 months.

Pain according to numerical visual pain scale.

Adverse events.7 days, 1, 3 and 6 months.

Adverse events.

Trial Locations

Locations (1)

Enrique Barez

🇪🇸

Vitoria-Gasteiz, Álava, Spain

© Copyright 2025. All Rights Reserved by MedPath